APA (7th ed.) Citation

N, S., A, A., GD, B., P, D. B., M, M., R, D., . . . M, G. (2020). Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: An Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Critical reviews in oncology/hematology, 154, 103066. https://doi.org/10.1016/j.critrevonc.2020.103066

Chicago Style (17th ed.) Citation

N, Silvestris, et al. "Management of Metabolic Adverse Events of Targeted Therapies and Immune Checkpoint Inhibitors in Cancer Patients: An Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) Multidisciplinary Consensus Position Paper." Critical Reviews in Oncology/hematology 154 (2020): 103066. https://doi.org/10.1016/j.critrevonc.2020.103066.

MLA (9th ed.) Citation

N, Silvestris, et al. "Management of Metabolic Adverse Events of Targeted Therapies and Immune Checkpoint Inhibitors in Cancer Patients: An Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) Multidisciplinary Consensus Position Paper." Critical Reviews in Oncology/hematology, vol. 154, 2020, p. 103066, https://doi.org/10.1016/j.critrevonc.2020.103066.